Drug Trial Radar · NCT06356194
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Apr 15, 2024
Primary completion
May 30, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir
Conditions
- Healthy Volunteer Study
Interventions
Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIKDrug
A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.Drug
A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR).Time frame: Day 2, Days 4-7, Days 14-17, Days 21-24
- To determine the effect of Bemnifosbuvir (BEM)/Ruzasvir (RZR) combination on the PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine)Time frame: Days 7-10, Day 12, Days 14-17, Days 21-24.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atea Study Site
Québec, Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.